8-K: QT Imaging's 2024 Revenue Soars Amidst Deepening Losses

QT Imaging Holdings, Inc. reported its audited 2024 financial results, showcasing significant revenue growth but also a substantial increase in net losses and operating expenses, alongside critical financing updates.

Summary

• Revenue for the year ended December 31, 2024, dramatically increased to $4,878,665, up from $40,355 in 2023, primarily driven by product sales.
• The company achieved a gross profit of $2,639,845 in 2024, a significant turnaround from a gross loss of $(94,633) in 2023.
• Net loss attributable to common stockholders widened to $(14,170,382) in 2024, compared to $(6,098,951) in 2023.
• Operating expenses more than doubled, reaching $14,816,852 in 2024, up from $4,913,326 in 2023, with significant increases in both research and development and selling, general and administrative costs.
• Cash used in operating activities increased to $(10,033,477) in 2024 from $(2,651,143) in 2023.
• Total liabilities increased to $15,624,957 as of December 31, 2024, from $12,018,561 as of December 31, 2023.
• The company completed a business combination (Merger) with GigCapital5, Inc. on March 4, 2024, and subsequently underwent a 3:1 reverse stock split effective October 23, 2025.
• Conditions for the 2024 Merger Consideration Earnout Shares, including formal FDA clearance for breast cancer screening, were not met.
• Subsequent to year-end, the company secured a $10.1 million senior secured term loan from Lynrock Lake Master Fund LP, repaid the Yorkville Note and Cable Car Loan, and completed an October 2025 Private Placement raising approximately $18.18 million.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with mixed sentiment. While significant revenue growth and successful capital raises are positive, the substantial increase in net losses, operating expenses, and negative operating cash flow, coupled with unmet earnout conditions, indicate ongoing financial challenges and a high burn rate.

Positives

• Revenue surged to $4,878,665 in 2024 from $40,355 in 2023, indicating strong market penetration and product adoption.
• The company achieved a gross profit of $2,639,845 in 2024, a significant improvement from a gross loss of $(94,633) in 2023.
• Cash and restricted cash increased substantially to $1,192,104 at year-end 2024 from $184,686 at year-end 2023.
• Secured significant financing post-year-end, including a $10.1 million term loan from Lynrock Lake and an $18.18 million private placement, bolstering liquidity.
• Entered into distribution agreements with NXC Imaging and Gulf Medical Co., projecting minimum order quantities (MOQs) of $18.0 million in 2025 and $27.0 million in 2026.

Negatives

• Net loss attributable to common stockholders significantly increased to $(14,170,382) in 2024 from $(6,098,951) in 2023.
• Operating expenses more than doubled to $14,816,852 in 2024, driven by increased research and development ($3,267,340) and selling, general and administrative costs ($11,549,512).
• Cash used in operating activities worsened to $(10,033,477) in 2024 from $(2,651,143) in 2023, indicating a high cash burn rate.
• The accumulated deficit grew to $(31,940,527) as of December 31, 2024, from $(17,770,145) in 2023.
• Total liabilities increased to $15,624,957 in 2024 from $12,018,561 in 2023.
• The conditions for the 2024 Merger Consideration Earnout Shares, including formal FDA clearance for breast cancer screening, were not met, resulting in no shares being issued for this period.

Risks

• The company has incurred net operating losses and negative cash flows from operations since inception and expects to continue incurring losses, requiring additional capital raises.
• Future capital requirements depend on growth rate, R&D spending, inventory purchases, and product enhancement costs, with no guarantee of obtaining financing on acceptable terms.
• Significant customer concentration exists, with NXC Imaging expected to make up a substantial portion of future revenues, posing a risk if contracts are terminated or not renewed.
• Dependence on a limited number of suppliers for critical components of the QT Breast Scanner could lead to significant development efforts if a supplier is lost.
• Potential delisting from the Nasdaq Stock Market is a risk, although the company has plans to relist and maintain listing on OTC Markets.

Future Outlook

Management believes that the additional cash received from the Lynrock Lake Term Loan and the October 2025 Private Placement, combined with anticipated revenue from minimum order quantities (MOQs) per the Amended Distribution Agreement with NXC Imaging and the Gulf Medical Distribution Agreement, will be sufficient to fund the company's current operating plan for at least the next 12 months. However, the company expects to continue incurring losses and will need to raise additional capital in the future, which may involve restrictive covenants or significant dilution to existing stockholders.

Management Comments

• "Management believes that the additional cash received for the Lynrock Lake Term Loan and from the October 2025 Private Placement, as well as the additional revenue from MOQs per the Amended Distribution Agreement and the Gulf Medical Distribution Agreement, will be sufficient to fund the Company’s current operating plan for at least the next 12 months."

Industry Context

StockSavvy.ai notes that the medical device sector, particularly in imaging, often requires substantial research and development investment and faces long regulatory pathways, which aligns with QT Imaging's increased R&D spending and ongoing efforts to secure FDA clearances. The company's strategy to improve global health outcomes with safe, affordable, and accessible medical imaging positions it in a competitive market segment, where rapid technological advancements and regulatory approvals are critical for success and market share.

Management Changes

Corporate Governance

Legal Proceedings

• Management is not aware of any pending claims that will have a material impact on the company's consolidated financial statements.

Related Party Transactions

• Convertible Notes Payable (2020 Notes) to three stockholders totaling $3,143,725 in principal and $550,430 in accrued interest as of December 31, 2024.
• A Working Capital Note to a stockholder for an aggregate principal amount of $705,000 as of December 31, 2024.
• The Extension Note of $1,560,000 due to a related party was cancelled on November 22, 2024, in exchange for 890,411 shares of common stock and 890,411 PIPE Warrants.
• A private placement on November 12, 2024, with certain board members for an aggregate purchase price of $999,998 in exchange for 570,775 shares of common stock and 570,775 PIPE Warrants.
• Management Services Agreement, Services Agreement, and Space and Equipment Sublease Agreement with John C. Klock, M.D. (former CEO and board member) and his Practice, which were all terminated on December 31, 2024.
• A $300,000 customer deposit from 303 Development Corporation (a related party) was refunded in June 2024 due to an order cancellation.
• Subsequent to year-end, the company entered into a $10.1 million senior secured term loan with Lynrock Lake Master Fund LP, a related party, on February 26, 2025.
• Subsequent to year-end, an April 2025 Private Placement for $500,000 was conducted with Dr. Avi Katz (Chairman) and Dr. Raluca Dinu (CEO).

Stakeholder Impact

• Shareholders: Experienced significant dilution from multiple equity issuances and a reverse stock split, with potential for further dilution if additional capital is raised through equity.
• Creditors: New senior secured term loan from Lynrock Lake and repayment of previous notes (Yorkville, Cable Car) have restructured the company's debt profile.
• Customers: Expansion of distribution agreements with NXC Imaging and Gulf Medical Co. indicates broader market reach and improved access to QT Breast Scanners.
• Employees: Stock-based compensation plans are in place, providing incentives, and the company's growth could lead to future opportunities.

Next Steps

• The company has submitted its application to relist on the Nasdaq Capital Market.
• Achieve 2025 Earnout Shares conditions, including annual revenue of at least $17.1 million and at least four breast scanner placements in the United States by September 30, 2025, with potential for additional shares based on new FDA indication or clinical-quality patient images with the open angle scanner.
• Achieve 2026 Earnout Shares conditions, including revenue of at least $30 million or a VWAP of $45.00 for 20 of 30 consecutive trading days by September 30, 2026, with potential for additional shares based on open angle scanner FDA clearance or positive clinical trial results.
• Interim disclosure requirements for ASU 2023-07 (Segment Reporting) become effective in the first quarter of 2025.
• The company is evaluating the impact of ASU 2023-09 (Income Tax Disclosures) and ASU 2024-03 (Expense Disaggregation Disclosures) on its financial statements.

Key Dates

Recommendation

While the company demonstrated impressive revenue growth and secured significant financing, the substantial increase in net losses and operating expenses, coupled with a worsening cash burn from operations, indicates ongoing financial instability. The recent capital raises provide a lifeline and the distribution agreements offer future revenue potential, but the failure to meet 2024 earnout conditions and the need for continuous financing suggest high risk. Investors should hold to monitor the execution of distribution agreements, progress on FDA clearances, and the company's ability to achieve profitability and manage its high burn rate.

Keywords

QT Imaging, QTIH, medical device, breast imaging, financial results, SEC filing, revenue growth, net loss, capital raise, FDA clearance, reverse stock split, operating expenses, liquidity